Safety, Performance of CEREGLIDE 92 Intermediate Catheter in Treatment of Acute Ischemic Stroke (NCT06386289) | Clinical Trial Compass
WithdrawnNot Applicable
Safety, Performance of CEREGLIDE 92 Intermediate Catheter in Treatment of Acute Ischemic Stroke
Stopped: Due to a change in innovation strategy
0Started 2025-09-01
Plain-language summary
The device is indicated for use in the revascularization of patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease
Who can participate
Age range18 Years – 90 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Diagnosis of acute ischemic stroke.
* NIHSS ≥6
* Baseline mRS ≤ 2
* Completed informed consent.
Exclusion Criteria:
* Known pregnancy.
* Life expectancy less than 90 days prior to stroke onset.
* Known Diagnosis of Dementia
* Treatment with heparin within 48 hours.
* Clinical history, past imaging or clinical judgement suggest that the intracranial occlusion is chronic.
* Computed tomography (CT) or Magnetic Resonance Imaging (MRI) evidence of recent/ fresh hemorrhage on presentation.
* Baseline CT or MRI showing mass effect
* Concurrent sino-venous thrombosis
* Currently participating in an investigational (drug, device, etc.) clinical trial, excluding trials in observational, natural history, and/or epidemiological studies not involving intervention and that will not confound study endpoints. Sponsor approval is required.
What they're measuring
1
First pass reperfusion
Timeframe: Intraprocedural
Trial details
NCT IDNCT06386289
SponsorCerenovus, Part of DePuy Synthes Products, Inc.